Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart disease study aims to unlock genetic secrets of dilated cardiomyopathy

NCT ID NCT03843255

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 2000 people with dilated cardiomyopathy (a weakened, enlarged heart) over several years to learn how genetics and heart scarring affect the disease. Participants give blood for genetic testing and have heart MRI scans. The goal is to improve diagnosis and pave the way for future personalized treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patients of any age with diagnosed DCM (part 1), and * Their family members with other heritable cardiovasacular disease (affected and unaffected), or other eligible patients with hypokinetic non-dilated cardiomyopathy (part 2)

Ages

Up to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PART 1 Inclusion Criteria: * Male or female participants of any age * Capacity to provide informed consent * Patients with a confirmed diagnosis of DCM * Affected family members of patients meeting diagnostic criteria for DCM Exclusion Criteria: * DCM attributed to chemotoxicity (from chemotherapeutic agents, drugs of abuse) * DCM attributed to systemic inflammatory myopathies (eg sarcoid, systemic lupus erythematosus) * Patients who lack capacity to consent for themselves * Patients with a confirmed history of coronary artery disease, assessed using standard UK clinical practice guidelines, defined as one or more of the following:- * \>50% narrowing, any major epicardial coronary artery on invasive or computed tomography coronary angiography * CMR suggestive of previous myocardial infarction of ≥2 segments of ≥50% infarction of the LV wall * Previous percutaneous coronary intervention or coronary bypass surgery * History of primary valvular heart disease or congenital heart disease * Severe, untreated or untreatable hypertension (systolic blood pressures routinely \>180 mm Hg and/or diastolic blood pressures \>120 mm Hg) PART 2 Inclusion Criteria: * Males or females of any age * Capacity to provide informed consent * Patients with hypokinetic non-dilated cardiomyopathy, or * Family members of DCM patients with possible or probable DCM or * Patients with a confirmed diagnosis of heritable cardiovascular disease or * Family members of patients with heritable cardiovascular disease, both affected and unaffected Exclusion Criteria: * Patients who lack capacity to consent for themselves * Patients with a confirmed history of coronary artery disease, assessed using standard UK clinical practice guidelines, defined as one or more of the following:- * \>50% narrowing, any major epicardial coronary artery on invasive or computed tomography coronary angiography * CMR suggestive of previous myocardial infarction of ≥2 segments of ≥50% infarction of the LV wall * Previous percutaneous coronary intervention or coronary bypass surgery * History of primary valvular heart disease or congenital heart disease * Severe, untreated or untreatable hypertension (systolic blood pressures routinely \>180 mm Hg and/or diastolic blood pressures \>120 mm Hg)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Glenfield Hospital

    Leicester, LE3 9QP, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, LS1 3EX, United Kingdom

  • Liverpool Heart and Chest Hospital NHS Foundation Trust

    Liverpool, L14 3PE, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

  • Royal Brompton & Harefield NHS Foundation Trust

    London, SW3 6NP, United Kingdom

  • Southampton General Hospital

    Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.